Klebsiella Pneumoniae Carbapenemase Resistant Associated Bacteremia or Pneumonia
Conditions
Keywords
Klebsiella , pneumonia, carbapenem-hydrolyzing lactamase, carbapenem-resistant Klebsiella (KPC), eradication,
Brief summary
Klebsiella pneumonia, inhabitant of the digestive tract, is a frequent nosocomial pathogen. It is currently the fourth most common cause of pneumonia and fifth most common cause of bacteremia in intensive care patients (1-3). The aim of the present randomized controlled trial is to assess the efficacy of non-absorbable oral antibiotics in the eradication of the KPC carrier state.
Interventions
DRUGColistin (Polymyxin E) 100mg x 4/d
Colistin (Polymyxin E) 100mg x 4/d
DRUGboth medications
PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
DRUGwill not receive PO treatment
will not receive PO treatment - will receive plecebo treatment
DRUGPO Garamycin 80mg x 4/d
PO Garamycin 80mg x 4/d
Sponsors
Rambam Health Care Campus
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Inclusion Criteria 1. Patient identified as a KPC carrier. 2. Patient capable to understand and sign informed consent 3. Age \> 18 4. Patient capable to receive oral medication
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The specific measure that will be used to determine the effect of the intervention(s): eradication rate (%). | twice a week | \- Is this outcome measure assessing a safety issue? Select: no |
Countries
Israel
Outcome results
None listed